Display options
Cite
Dickschen KJ, Willmann S, Hempel G, et al. Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels. Front Pharmacol. 2017;8:67doi: 10.3389/fphar.2017.00067.
Dickschen, K. J., Willmann, S., Hempel, G., & Block, M. (2017). Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels. Frontiers in pharmacology, 867. https://doi.org/10.3389/fphar.2017.00067
Dickschen, Kristin J R, et al. "Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels." Frontiers in pharmacology vol. 8 (2017): 67. doi: https://doi.org/10.3389/fphar.2017.00067
Dickschen KJ, Willmann S, Hempel G, Block M. Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels. Front Pharmacol. 2017 Mar 14;8:67. doi: 10.3389/fphar.2017.00067. eCollection 2017. PMID: 28382001; PMCID: PMC5361661.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2017 Mar 14;8:67. doi: 10.3389/fphar.2017.00067. eCollection 2017.

Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels.

Frontiers in pharmacology

Kristin J R Dickschen, Stefan Willmann, Georg Hempel, Michael Block

Affiliations

  1. Computational Systems Biology, Bayer AG Leverkusen, Germany.
  2. Clinical Pharmacometrics, Bayer Pharma AG Wuppertal, Germany.
  3. Clinical Pharmacy, Department of Pharmaceutical and Medical Chemistry, University of Muenster Muenster, Germany.

PMID: 28382001 PMCID: PMC5361661 DOI: 10.3389/fphar.2017.00067

[No abstract available.]

Keywords: CYP2D6; PBPK modeling; drug holidays; endoxifen; genotype; population simulation; tamoxifen

References

  1. J Pharmacol Exp Ther. 2006 Aug;318(2):503-12 - PubMed
  2. Clin Pharmacol Ther. 2006 Jul;80(1):61-74 - PubMed
  3. Expert Rev Mol Diagn. 2013 May;13(4):349-65 - PubMed
  4. Pharmacogenomics J. 2004;4(3):143-53 - PubMed
  5. Arzneimittelforschung. 1996 Apr;46(4):418-22 - PubMed
  6. Cancer Res. 2009 Mar 1;69(5):1722-7 - PubMed
  7. Br J Cancer. 2008 Dec 2;99(11):1763-8 - PubMed
  8. J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64 - PubMed
  9. Springerplus. 2014 Jun 05;3:285 - PubMed
  10. Ther Drug Monit. 2012 Aug;34(4):422-31 - PubMed
  11. Lancet. 1998 May 16;351(9114):1451-67 - PubMed
  12. Lancet. 1992 Jan 11;339(8785):71-85 - PubMed
  13. Ann Oncol. 2006 Feb;17(2):183-4 - PubMed
  14. Cancer Chemother Pharmacol. 2012 Jul;70(1):75-81 - PubMed
  15. JAMA. 2009 Oct 7;302(13):1429-36 - PubMed
  16. Breast Care (Basel). 2008;3(1):43-50 - PubMed
  17. Cancer. 2007 Mar 1;109(5):832-9 - PubMed
  18. Clin Pharmacol Ther. 2011 May;89(5):708-17 - PubMed
  19. Expert Opin Drug Metab Toxicol. 2007 Apr;3(2):235-49 - PubMed
  20. J Clin Oncol. 2013 Jan 10;31(2):176-80 - PubMed
  21. J Clin Oncol. 2010 Sep 20;28(27):4120-8 - PubMed
  22. Pharmacogenomics J. 2009 Aug;9(4):258-64 - PubMed
  23. Front Pharmacol. 2012 May 21;3:92 - PubMed
  24. Breast Cancer Res Treat. 2004 May;85(2):151-9 - PubMed
  25. J Clin Oncol. 2013 Jul 20;31(21):2755-6 - PubMed
  26. Cancer Chemother Pharmacol. 2005 May;55(5):471-8 - PubMed
  27. Clin Chem. 2009 Oct;55(10 ):1770-82 - PubMed
  28. Ann Oncol. 2009 Mar;20(3):401-2 - PubMed
  29. Br J Cancer. 2013 Apr 16;108(7):1515-24 - PubMed
  30. Ann Oncol. 2009 Mar;20(3):431-6 - PubMed
  31. J Clin Oncol. 2014 Jul 20;32(21):2255-69 - PubMed
  32. Lancet. 2005 May 14-20;365(9472):1687-717 - PubMed
  33. J Clin Oncol. 2007 Nov 20;25(33):5187-93 - PubMed
  34. Clin Cancer Res. 2010 Sep 1;16(17):4468-77 - PubMed
  35. J Clin Oncol. 2011 Dec 1;29(34):4589-90; author reply 4590-1 - PubMed
  36. J Clin Oncol. 2010 May 10;28(14):2423-9 - PubMed

Publication Types